Who are Placebo matched phentermine/topiramate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matched-phentermine-topiramate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo matched phentermine/topiramate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo matched phentermine/topiramate (Placebo matched phentermine/topiramate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine + anticonvulsant combination. Area: Obesity/Weight Management.

phase 3 Sympathomimetic amine + anticonvulsant combination Norepinephrine release (phentermine); carbonic anhydrase, GABA receptors, glutamate receptors (topiramate) Obesity/Weight Management Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matched phentermine/topiramate (Placebo matched phentermine/topiramate) — VIVUS LLC. Phentermine/topiramate is a combination that suppresses appetite through sympathomimetic stimulation and enhances satiety through carbonic anhydrase inhibition and GABAergic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo matched phentermine/topiramate TARGET	Placebo matched phentermine/topiramate	VIVUS LLC	phase 3	Sympathomimetic amine + anticonvulsant combination	Norepinephrine release (phentermine); carbonic anhydrase, GABA receptors, glutamate receptors (topiramate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine + anticonvulsant combination class)

VIVUS LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matched phentermine/topiramate — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matched-phentermine-topiramate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab